AZN.UK

12,574

+0.62%↑

GSK

1,633.5

-1.33%↓

HLN.UK

328.4

-0.79%↓

STJ

1,295

+1.37%↑

HIK

1,840

+1.43%↑

AZN.UK

12,574

+0.62%↑

GSK

1,633.5

-1.33%↓

HLN.UK

328.4

-0.79%↓

STJ

1,295

+1.37%↑

HIK

1,840

+1.43%↑

AZN.UK

12,574

+0.62%↑

GSK

1,633.5

-1.33%↓

HLN.UK

328.4

-0.79%↓

STJ

1,295

+1.37%↑

HIK

1,840

+1.43%↑

AZN.UK

12,574

+0.62%↑

GSK

1,633.5

-1.33%↓

HLN.UK

328.4

-0.79%↓

STJ

1,295

+1.37%↑

HIK

1,840

+1.43%↑

AZN.UK

12,574

+0.62%↑

GSK

1,633.5

-1.33%↓

HLN.UK

328.4

-0.79%↓

STJ

1,295

+1.37%↑

HIK

1,840

+1.43%↑

Search

PureTech Health Plc

Abrir

140 0.72

Visão Geral

Variação de preço das ações

24h

Atual

Mín

137.2

Máximo

142.4

Indicadores-chave

By Trading Economics

Rendimento

70M

Vendas

4M

P/E

Médio do Setor

9.969

35.739

EPS

-0.19

Margem de lucro

1,727.216

Funcionários

56

EBITDA

102M

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

313M

Abertura anterior

139.28

Fecho anterior

140

PureTech Health Plc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de out. de 2025, 23:30 UTC

Ações em Alta

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 de out. de 2025, 21:21 UTC

Ganhos

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 de out. de 2025, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 de out. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 de out. de 2025, 23:39 UTC

Conversa de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 de out. de 2025, 23:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 de out. de 2025, 23:00 UTC

Conversa de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Scales's JV Buyout Lauded by Bull -- Market Talk

2 de out. de 2025, 22:54 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Forex and Fixed Income Roundup: Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 de out. de 2025, 22:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de out. de 2025, 21:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 de out. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Energy & Utilities Roundup: Market Talk

2 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de out. de 2025, 20:49 UTC

Aquisições, Fusões, Aquisições de Empresas

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 de out. de 2025, 20:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 de out. de 2025, 19:20 UTC

Conversa de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 de out. de 2025, 19:10 UTC

Conversa de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 de out. de 2025, 19:04 UTC

Conversa de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 de out. de 2025, 18:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 de out. de 2025, 18:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 de out. de 2025, 18:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 de out. de 2025, 18:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparação entre Pares

Variação de preço

PureTech Health Plc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
help-icon Live chat